A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: Design and statistical methods of the PERSEUS clinical program

Trials

Volumn 11, Issue , 2010, Pages

  Allocco, Dominic J ^a   Cannon, Louis A ^b   Britt, Amy ^a   Heil, John E ^a   Nersesov, Andrey ^a   Wehrenberg, Scott ^a   Dawkins, Keith D ^a   Kereiakes, Dean J ^c  

^a BOSTON SCIENTIFIC CORPORATION   (United States)

^b Northern Michigan Regional Hospital   (United States)

^c The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PACLITAXEL; TICLOPIDINE; CARDIOVASCULAR AGENT; CHROMIUM DERIVATIVE; PLATINUM;

ANGIOGRAPHY; ARTICLE; BAYES THEOREM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ELUTING STENT; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; METHODOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAFETY; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS; STENT THROMBOSIS; ANGIOCARDIOGRAPHY; AUSTRALIA; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; HOSPITALIZATION; INSTRUMENTATION; MULTICENTER STUDY; NEW ZEALAND; PROSTHESIS; RADIOGRAPHY; SINGAPORE; STENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNITED STATES;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; AUSTRALIA; BAYES THEOREM; CARDIOVASCULAR AGENTS; CHROMIUM ALLOYS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DATA INTERPRETATION, STATISTICAL; DRUG-ELUTING STENTS; HUMANS; NEW ZEALAND; PACLITAXEL; PLATELET AGGREGATION INHIBITORS; PLATINUM; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; SINGAPORE; SINGLE-BLIND METHOD; STENTS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77249108463     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-11-1     Document Type: Article

References (29)

1. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME, . TAXUS-IV Investigators A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004, 350:221-231. 10.1056/NEJMoa032441, 14724301, TAXUS-IV Investigators.
2. Turco MA, Ormiston JA, Popma JJ, Mandinov L, O'Shaughnessy CD, Mann T, McGarry TF, Wu CJ, Chan C, Webster MW, Hall JJ, Mishkel GJ, Cannon LA, Baim DS, Koglin J. Polymer-based, paclitaxel-eluting TAXUS Liberte stent in de novo lesions: The Pivotal TAXUS ATLAS Trial. J Am Coll Cardiol 2007, 49:1676-1683. 10.1016/j.jacc.2007.01.069, 17448368.
3. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007, 356:998-1008. 10.1056/NEJMoa067193, 17296824.
4. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J, Fleckenstein M, Neumann FJ, Sattelberger U, Schmitt C, Müller M, Dirschinger J, Schömig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003, 41:1283-1288. 10.1016/S0735-1097(03)00119-0, 12706922.
5. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ, Fleckenstein M, Pfafferott C, Seyfarth M, Schomig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001, 103:2816-2821.
6. Hannan EL, Wu C, Walford G, Holmes DR, Jones RH, Sharma S, King SB. Incomplete Revascularization in the Era of Drug-Eluting Stents: Impact on Adverse Outcomes. J Am Coll Cardiol Intv 2009, 2:17-25.
7. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME, . TAXUS V Investigators Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005, 294:1215-1223. 10.1001/jama.294.10.1215, 16160130, TAXUS V Investigators.
8. Lasala JM, Cox DA, Lewis SJ, Tadros PN, Haas RC, Schweiger MJ, Chhabra A, Untereker WJ, Starzyk RM, Mascioli SR, Dawkins KD, Baim DS. Expanded Use of the TAXUS Express Stent: 2-Year Insights on Safety from the 7500 Patient ARRIVE Registry Programme. EuroIntervention 2009, 5:67-77.
9. Ahmed W, Zambahari R, Al-Rashdan I, Al NA, Saeed FA, Mascioli S. One-Year Outcomes with the TAXUS Liberte Stent in the Real World: The TAXUS OLYMPIA Registry (Phase I). J Interv Cardiol 2008, 21:512-518. 10.1111/j.1540-8183.2008.00395.x, 18973513.
10. Ormiston JA, Mahmud E, Turco MA, Popma JJ, Weissman N, Cannon LA, Mann T, Lucca MJ, Lim S-T, Hall JJ, McClean D, Dobies D, Mandinov L, Baim DS. Direct Stenting With the TAXUS Liberte Drug-Eluting Stent: Results From the TAXUS ATLAS DIRECT STENT Study. J Am Coll Cardiol Intv 2008, 1:150-160.
11. Turco MA, Ormiston JA, Popma JJ, Hall JJ, Mann T, Cannon LA, Webster MWI, Mishkel GJ, O'Shaughnessy CD, McGarry TF, Mandinov L, Dawkins KD, Baim DS. Reduced Risk of Restenosis in Small Vessels and Reduced Risk of Myocardial Infarction in Long Lesions With the New Thin-Strut TAXUS Liberté Stent: 1-Year Results From the TAXUS ATLAS Program. J Am Coll Cardiol Intv 2008, 1:699-709.
12. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, . Academic Research Consortium Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 115:2344-2351. 10.1161/CIRCULATIONAHA.106.685313, 17470709, Academic Research Consortium.
13. King SB, Smith SC, Hirshfeld JW, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, Whitlow PL, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008, 117:261-295. 10.1161/CIRCULATIONAHA.107.188208, 18079354.
14. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990, 82:1193-1202.
15. Ellis SG, Popma JJ, Lasala JM, Koglin JJ, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Stone GW. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005, 45:1193-1200. 10.1016/j.jacc.2004.11.063, 15837248.
16. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov 2006, 5:27-36. 10.1038/nrd1927, 16485344.
17. Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials - Draft Guidance for Industry and FDA Staff. 2006,
18. Pennello G, Thompson L. Experience with reviewing Bayesian medical device trials. J Biopharm Stat 2008, 18:81-115. 10.1080/10543400701668274, 18161543.
19. Turco M, Grube E. Taxus Clinical Update-Experts discuss the current role of the Taxus stent. Cardiac Intervent Today 2008, September:34-39.
20. Malec D. A closer look at combining data among a small number of binomial experiments. Stat Med 2001, 20:1811-1824. 10.1002/sim.782, 11406843.
21. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ, . SPIRIT III Investigators Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease: A Randomized Trial. JAMA 2008, 299:1903-1913. 10.1001/jama.299.16.1903, 18430909, SPIRIT III Investigators.
22. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. The Lancet 2008, 372:1163-1173.
23. ASTM Standard F2079, Standard Test Method for Measuring Intrinsic Elastic Recoil of Balloon-Expandable Stents. 2002, West Conshohocken, PA: ASTM International.
24. Steiner R. ASM Handbook:: Properties and Selection: Irons, Steels, and High-Performance Alloys 1990, 1. Materials Park, OH: ASM International, 10.
25. Thompson C, Huibregtse B, Poff B, Wilson G. Time Dependent Vascular and Myocardial Responses of a Second Generation, Small Vessel, Paclitaxel-Eluting Stent Platform. Catheter Cardiovasc Interv 2009, 73:597-604. 10.1002/ccd.21890, 19180652.
26. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 1999, 10:499-506. 10.1097/00041433-199912000-00004, 10680043.
27. Wilson GJ, Polovick JE, Huibregtse BA, Poff BC. Overlapping paclitaxel-eluting stents: Long-term effects in a porcine coronary artery model. Cardiovasc Res 2007, 76:361-372. 10.1016/j.cardiores.2007.07.004, 17716637.
28. Nakazawa G, Finn AV, Kolodgie FD, Virmani R. A review of current devices and a look at new technology: drug-eluting stents. Expert Rev Med Devices 2009, 6:33-42. 10.1586/17434440.6.1.33, 19105778.
29. Seifert PS, Huibregtse BA, Polovick J, Poff B. Early vascular response to overlapped paclitaxel-eluting stents in swine coronary arteries. Cardiovasc Revasc Med 2007, 8:251-258. 10.1016/j.carrev.2007.08.002, 18053947.